On December 3, 2003, Suga, A.; Kubota, H.; Miura, M.; Sasuga, D.; Moritani, H. published a patent.SDS of cas: 34662-29-8 The title of the patent was Preparation of tetrahydropyranalkyl carboxamide derivatives as inhibitors of apo β-related lipoprotein secretion. And the patent contained the following:
A novel tetrahydropyran derivative which has an excellent apo B-related lipoprotein secretion-inhibiting activity of the following general formula (I) or a salt thereof are prepared wherein R1 and R3 are the same or different and each represents H or lower alkyl; R2 is H, halogen, Ra-lower alkyl, or R20O-CO-; Ra is H, R21O-CO-, R22R23N-, R24R25N-CO-, R26O-cyano, or optionally-substituted hetero ring; R4, R5, R6 and R7 are the same or different and each is H, halogen, haloalkyl, cyano, lower alkyl, lower alkyl-O-, R21O-CO-lower alkyl-, R27-CO-, or R28R29N-S(O)2-; R8 and R9 are the same or different and each is H, lower alkyl, R30-lower alkyl-, R31R32N-, optionally- substituted hetero ring, or R33R34R35C-; R8 and R9 may together form optionally-substituted hetero ring-; X is N or CR36; R20, R22 to R26, R28, R29, R32 and R36 are the same or different and each is H or lower alkyl; R21 is H, lower alkyl, or aryl-lower alkyl-; R27 is HO-, lower alkyl-O-, or optionally-substituted hetero ring-, or lower alkyl-O-; R30 represents optionally-substituted aryl, optionally-substituted hetero ring-, or lower alkyl-O-; R31 represents optionally-substituted aryl, or optionally-substituted hetero ring-; R33 represents HO-lower alkyl-, or optionally-substituted hetero ring-lower alkyl-; R34 represents optionally-substituted aryl-. Thus, e.g., II was prepared by hydrolysis of corresponding Et ester (preparation given). In assays to evaluate apo β-related lipoprotein secretion-inhibiting activity, selected compounds of I possessed IC50 values ranging from 1.7-40 nM. As inhibitors of apo β-related lipoprotein secretion, I have excellent blood cholesterol and triglyceride-lowering effect, and are useful as remedies for hyperlipemia, arteriosclerosis, obesity and pancreatitis. The experimental process involved the reaction of 3-Chloro-4-nitrobenzonitrile(cas: 34662-29-8).SDS of cas: 34662-29-8
The Article related to pyran tetrahydro derivative preparation lipoprotein secretion inhibitor, pyranalkylcarboxamide derivative preparation hyperlipemia arteriosclerosis obesity pancreatitis, Heterocyclic Compounds (One Hetero Atom): Pyrans and other aspects.SDS of cas: 34662-29-8
Referemce:
Nitrile – Wikipedia,
Nitriles – Chemistry LibreTexts